Redirecting innovation in U.S. health care

"Our work for this project focused on identifying promising policy options to change which medical technologies are created in the first place, with these two related policy goals:

1. Reduce total health care spending with the smallest possible loss of health benefits.
2. Ensure that new medical products that increase spending are accompanied by health benefits that are worth the spending increases."

Redirecting innovation in U.S. health care: options to decrease spending and increase value
S Garber, SM Gates, EB Keeler, ME Vaiana, AW Mulcahy, C Lau, AL Kellermann
RAND Corporation
2014

Read more here.

Capturing value from health technologies in lean times

"The adoption of new health technologies brings potential improvements to quality of life as well as new costs for provincial healthcare systems."

Capturing value from health technologies in lean times
Commentary no.396
A Blomqvist, C Busby, D Husereau
C.D. Howe Institute
December 2013

Read more here.

Toward new models for innovative governance of biomedicine and health technologies

"To efficiently translate biomedicine and health technologies from the laboratory bench to the bedside, governance frameworks are having to change to take into account the complexity of the field, using new (and often) iterative regulatory processes."

Toward new models for innovative governance of biomedicine and health technologies
OECD Science, Technology and Industry Policy Papers No.11
December 2013

Read more here.

Uncertainty, evidence and irrecoverable costs

"This research was commissioned to inform when NICE should approve health technologies only in research (OIR) or with research (AWR)."

Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies
K Claxton, S Palmer, L Longworth, L Bojke, S Griffin, C McKenna, M Soares, E Spackman, J Youn
Centre for Health Economics
October 2011

Read more here.